1. An Integrated Care Pathway for depression in adolescents: protocol for a Type 1 Hybrid Effectiveness-implementation, Non-randomized, Cluster Controlled Trial
- Author
-
Darren B. Courtney, Melanie Barwick, Bahar Amani, Andrea T. Greenblatt, Madison Aitken, Karolin R. Krause, Brendan F. Andrade, Kathryn Bennett, Kristin Cleverley, Amanda A. Uliaszek, Claire de Oliveira, Lisa D. Hawke, Jo Henderson, Wei Wang, Priya Watson, Amy Gajaria, Amanda S. Newton, Stephanie Ameis, Jacqueline Relihan, Matthew Prebeg, Sheng Chen, and Peter Szatmari
- Subjects
Adolescent ,Depression ,Integrated care pathway ,Measurement-based care ,Implementation ,Psychiatry ,RC435-571 - Abstract
Abstract Introduction Our group developed an Integrated Care Pathway to facilitate the delivery of evidence-based care for adolescents experiencing depression called CARIBOU-2 (Care for Adolescents who Receive Information ‘Bout OUtcomes, 2nd iteration). The core pathway components are assessment, psychoeducation, psychotherapy options, medication options, caregiver support, measurement-based care team reviews and graduation. We aim to test the clinical and implementation effectiveness of the CARIBOU-2 pathway relative to treatment-as-usual (TAU) in community mental health settings. Methods and analysis We will use a Type 1 Hybrid Effectiveness-Implementation, Non-randomized Cluster Controlled Trial Design. Primary participants will be adolescents (planned n = 300, aged 13–18 years) with depressive symptoms, presenting to one of six community mental health agencies. All sites will begin in the TAU condition and transition to the CARIBOU-2 intervention after enrolling 25 adolescents. The primary clinical outcome is the rate of change of depressive symptoms from baseline to the 24-week endpoint using the Childhood Depression Rating Scale—Revised (CDRS-R). Generalized mixed effects modelling will be conducted to compare this outcome between intervention types. Our primary hypothesis is that there will be a greater rate of reduction in depressive symptoms in the group receiving the CARIBOU-2 intervention relative to TAU over 24 weeks as per the CDRS-R. Implementation outcomes will also be examined, including clinician fidelity to the pathway and its components, and cost-effectiveness. Ethics and dissemination Research ethics board approvals have been obtained. Should our results support our hypotheses, systematic implementation of the CARIBOU-2 intervention in other community mental health agencies would be indicated.
- Published
- 2024
- Full Text
- View/download PDF